Print

TAMOVAC-01-MZ

Safety and Immunogenicity Study of a DNA Priming and MVA Boosting Strategy of HIV Vaccine

Trial Details:

I Completed
Instituto Nacional de Sa?de, Mozambique; Swedish Institute for Communicable Disease Control, Sweden; European and Developing Countries Clinical Trials Partnership (EDCTP) August 01, 2011
HIVIS-DNA,MVA-CMDR DNA Env A, B and C and Rev B while pool 2 comprised plasmids encoding Gag A, B and RTmut B; Pox gag-pol CM 240, env CM235
HIVIS-DNA DNA
MVA-CMDR Viral Vector - Pox
Mozambique 24
NCT01407497
http://clinicaltrials.gov/ct2/show/NCT01407497?term=hiv+vaccine&lup_s=07%2F04%2F2011&lup_d=30